Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 22:37 ET | Source: Belite Bio, Inc

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...
December 01, 2025 16:20 ET | Source: Belite Bio, Inc

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...
December 01, 2025 06:00 ET | Source: Belite Bio, Inc

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met...
November 10, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential...
November 03, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...
November 02, 2025 09:00 ET | Source: Belite Bio, Inc

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a...
October 29, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
October 16, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the 2025 Maxim Growth Summit

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
October 15, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a...
September 12, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation...